Related Experiment Videos
Cell lines for drug discovery: elevating target-protein levels using engineered transcription factors
Pei-Qi Liu1, Magda F Morton, Andreas Reik
1Sangamo BioSciences, Inc., Point Richmond Technology Center, Richmond, CA 94804, USA.
Journal of Biomolecular Screening
|March 10, 2004
Summary
Researchers developed a novel method to boost drug discovery by activating endogenous genes using engineered transcription factors. This approach overcomes limitations of cDNA use and enables high-quality bioassays for pharmaceutical research.
Area of Science:
- Molecular Biology
- Pharmacology
- Biotechnology
Background:
- High-throughput bioassays are crucial for drug discovery and lead optimization.
- Current assays often rely on cell lines with specific drug target expression.
- Limitations include insufficient expression levels in natural cell lines and patent restrictions on cDNA use.
Purpose of the Study:
- To develop a method for activating endogenous genes without using isolated cDNA.
- To create a high-quality bioassay for drug discovery.
- To demonstrate the applicability of engineered transcription factors for gene activation.
Main Methods:
- Engineered transcription factors with Cys2-His2 zinc finger DNA-binding domains were utilized.
- These factors were designed to activate endogenous gene expression.
- A cell line for a G-protein-coupled receptor bioassay was generated using this method.
Main Results:
- Successful activation of an endogenous gene of interest was achieved without cDNA.
- A pharmacologically validated G-protein-coupled receptor bioassay was established.
- The method demonstrated high signal-to-noise ratio for assay quality.
Conclusions:
- Engineered transcription factors offer a viable alternative to cDNA for activating endogenous genes.
- This technology can overcome limitations in current drug discovery bioassays.
- The approach is broadly applicable to any gene of pharmaceutical importance across various cell types.